Eversept Partners LP purchased a new position in shares of Savara Inc. (NASDAQ:SVRA – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 170,195 shares of the company’s stock, valued at approximately $1,026,000.
A number of other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after purchasing an additional 3,205 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the last quarter. Xponance LLC acquired a new position in Savara during the fourth quarter valued at approximately $66,000. CIBC Bancorp USA Inc. acquired a new stake in Savara in the third quarter worth $44,000. Finally, Prudential Financial Inc. acquired a new position in shares of Savara in the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 87.93% of the company’s stock.
Analysts Set New Price Targets
SVRA has been the subject of several recent analyst reports. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. William Blair set a $10.00 target price on shares of Savara in a research note on Monday, March 16th. Oppenheimer started coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Savara presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.
Savara Stock Up 1.5%
SVRA stock opened at $5.38 on Thursday. Savara Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $7.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -9.61 and a beta of 0.26. The business’s fifty day moving average price is $5.27 and its two-hundred day moving average price is $5.60.
Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, equities analysts anticipate that Savara Inc. will post -0.57 earnings per share for the current year.
About Savara
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Recommended Stories
- Five stocks we like better than Savara
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
